Proteins do not interact the way components on a circuit board do. Identical components such as resistors can be placed on the same circuit board and not interfere with one another, because the wiring keeps them connected only to components they were intended to interact with. Proteins, however, can diffuse throughout the cellular compartment that contains them, interacting with any suitable binding partners.
Evolution has found a solution to orthogonal signalling that still allows cells to use the same protein components for multiple processes (
Bhattacharyya et al. 2006). Classes of proteins, such as kinases, share a common mechanism of action but can act on a variety of targets. This is often achieved by varying combinations of adapter domains and effector domains. Signalling protein interactions are often mediated by events such as phosphorylation that change binding affinities and ‘rewire’ the network (
Pawson 2007).
Prokaryotic two-component signalling systems provide a simple model system for studying protein interactions. Canonical two-component systems consist of a membrane-bound receptor with ligand-dependent histidine kinase (HK) activity and a response regulator (RR) protein, usually a transcription factor (
West & Stock 2001).
The rational design of two-component signalling systems has recently been demonstrated (
Skerker et al. 2008). Multiple sequence alignments of HK and RR pairs identified residues that covaried, representing interacting partners. Modification of as few as three interacting residues in the HK EnvZ (an
E. coli osmolarity sensor) switched the EnvZ HK phosphorylation specificity from its cognate RR OmpR to the non-cognate RR RstA, which is not normally induced by osmotic changes. Additionally, the RR specificity of EnvZ was switched to that of CC1181, a
Caulobacter crecentus sensor protein. This research establishes a protocol for the rational design of two-component systems, as well as validating methods of HK–RR interaction prediction. The existence of two-component systems in eukaryotes (
Saito 2001) implies that novel HK–RR pairs could augment eukaryotic devices as well.
Eukaryotic signalling cascades are usually more complex than two-component systems, but eukaryotic signalling proteins can still be reprogrammed to accept new inputs. For example, a guanine nucleotide exchange factor (GEF) was modified to be responsive to protein kinase A (PKA;
Yeh et al. 2007). Active GEFs catalyse the exchange of GDP for GTP bound to Rho GTPases, and, in turn, GTP-bound Rho activates downstream effectors (
Rossman et al. 2005). To build a synthetic GEF, researchers replaced the cognate autoinhibitory domain of the CDC42-specific GEF Itsn1 with a PKA-dependent autoinhibitory domain, leaving the GEF catalytic domain intact (;
Yeh et al. 2007). The addition of forskolin, a PKA activator, induces production of filopodia in mammalian cells, indicating Itsn1 signalling. Substituting different GEF catalytic domains also produced new signalling behaviours, and signalling cascades involving two synthetic GEFs were also functional (
Yeh et al. 2007).
Protein domains can be combined to produce novel switch-like behaviour. A chimeric protein with two separate ligand-binding domains could act as a switch or an OR gate if only one ligand-binding domain could be occupied at a time. To isolate new protein switches, researchers overlapped functional ligand-binding domains and peptides in chimeric proteins, such that correct folding of one domain would disrupt folding of the other (
Sallee et al. 2007). Out of 25 candidates, seven chimeric proteins yielded functional switches, with domains that are unstructured in the absence of ligand showing the highest likelihood of success (
Sallee et al. 2007).
Protein ligands that bind cell surface receptors can also be used as modular regulatory elements. One such device, a chimeric-activating protein, was constructed by connecting an epidermal growth factor (EGF) ligand and an interferonα-2a (IFNα-2a) ligand via a flexible linker (
Cironi et al. 2008). The EGF ligand acts as a targeting element, binding the EGF receptor (EGFR). The IFNα-2a ligand triggers the desired action of the device, binding IFNα-2a–IFNα receptor 2 (IFNAR2) and activating the Jak–Stat pathway (
Platanias 2005). In the chimeric activator, the IFNα-2a ligand was mutated to reduce its binding affinity for IFNAR2. Reducing IFNα-2a binding affinity had the desired effect: IFNα-2a-mediated activation of the Jak–Stat pathway occurs only when both EGFR and IFNAR2 were present on the cell surface. EGF binding to EGFR brings IFNα-2a closer to the cell surface, increasing the likelihood of IFNα-2a–IFNAR2 binding and subsequent Jak–Stat signalling. As well as having therapeutic applications, chimeric activators could be incorporated into synthetic devices for intercellular signalling (
Cironi et al. 2008).
These synthetic protein devices demonstrate that the rearrangement of natural protein modules can yield new behaviours. To achieve protein–protein interactions that are truly orthogonal to an existing protein network, however, it may be necessary to design new protein interactions. There is evidence that new types of signalling, such as tyrosine kinase signalling, evolved in response to the saturation of previous signalling networks (
King et al. 2003;
Bhattacharyya et al. 2006). The engineering of novel signalling systems may permit synthetic devices to operate in cells without the interference of the endogenous protein network.
Modification of protein interfaces and binding pockets (as opposed to the rearrangement of modular elements discussed previously) has proven to be an effective method of altering protein specificity. Computational modelling of protein interfaces is often similar to
ab initio modelling of whole proteins, although the scope of the model is reduced to the interface in question (
Kortemme & Baker 2004). By modifying the interacting surface of one protein and predicting compensating mutations in a binding partner protein, natural protein–protein interfaces have been successfully redesigned (
Kortemme et al. 2004). Similarly, the rational design of ligand-binding pockets led to engineered periplasmic binding protein receptors capable of binding trinitrotoluene,
l-lactate and serotonin (
Looger et al. 2003).